Loading patent…
AssigneePlasmarker Biotechnology Co., Ltd
InventorsKai-cheng LI, Pu YOU
Estimating the term…
The present application relates to a digested DDIT4L product as a diagnostic marker for Alzheimer's disease, and use thereof in diagnosing Alzheimer's disease. In particular, the present application relates to use of a substance for detecting a digested intron retention (DIR) product encoding DNA-damage-inducible transcript 4 like (DDIT4L) in a sample of a subject in preparing a product for diagnosing Alzheimer's disease or a mild cognitive disorder and/or assessing (e.g., grading or staging) cognitive disorder progression, a related product thereof, and a method for screening a medicament using the DIR product.
A method for diagnosing cognitive impairment or a neurodegenerative disease, and/or evaluating progression of said cognitive impairment or said neurodegenerative disease, comprising the step of:
A diagnostic kit, comprising a substance for detecting a DNA damage-inducible transcript 4-like DDIT4L intron retention spliced product DIR, and/or a nucleic acid encoding said DIR, wherein said diagnostic kit is for use in diagnosis of cognitive impairment, and/or evaluation of progression of said cognitive impairment;
A medicament screening method, comprising the step of:
Dependencies are inferred from the claim text.